Neonc Technologies (NASDAQ:NTHI) President Acquires $48,900.00 in Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) President Amir Heshmatpour bought 10,000 shares of the business’s stock in a transaction dated Friday, April 10th. The stock was acquired at an average cost of $4.89 per share, for a total transaction of $48,900.00. Following the completion of the acquisition, the president directly owned 3,042,000 shares in the company, valued at approximately $14,875,380. This trade represents a 0.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Neonc Technologies Price Performance

Shares of Neonc Technologies stock opened at $5.44 on Monday. The firm’s fifty day simple moving average is $8.56 and its 200-day simple moving average is $9.03. Neonc Technologies Holdings, Inc. has a 12 month low of $3.20 and a 12 month high of $12.99.

Hedge Funds Weigh In On Neonc Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC grew its position in Neonc Technologies by 5,314.8% in the 4th quarter. Barclays PLC now owns 9,151 shares of the company’s stock valued at $76,000 after buying an additional 8,982 shares during the last quarter. Foundations Investment Advisors LLC purchased a new position in Neonc Technologies in the 3rd quarter valued at $100,000. SLT Holdings LLC purchased a new position in Neonc Technologies in the 3rd quarter valued at $100,000. Goldman Sachs Group Inc. purchased a new position in Neonc Technologies in the 4th quarter valued at $124,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in Neonc Technologies in the 4th quarter valued at $126,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on NTHI shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neonc Technologies in a report on Friday, March 27th. Zacks Research raised shares of Neonc Technologies to a “hold” rating in a report on Wednesday, January 14th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce”.

Neonc Technologies Company Profile

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.